Merck & Co. (MRK)
(Delayed Data from NYSE)
$108.70 USD
-1.05 (-0.96%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$108.70 USD
-1.05 (-0.96%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
Zacks News
Merck (MRK) to Supply Coronavirus Treatment to U.S. Government
by Zacks Equity Research
Merck (MRK) inks an agreement with the Government of United States for supplying MK-7110, being developed for treating patients with serious COVID-19, if approved.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $79.42 in the latest trading session, marking a +0.16% move from the prior day.
Clovis' (CLVS) Rubraca Confirmatory Study Meets Endpoint
by Zacks Equity Research
Clovis' (CLVS) Rubraca achieves significant improvement in progression free survival compared to chemotherapy in late-stage confirmatory study for BRCA-mutated ovarian cancer indication.
3 Large Drugmakers Set to Rule the Sector in 2021
by Kinjel Shah
Large Cap Pharmaceuticals industry players maintain a cautious outlook after mixed Q3 show. COVID-19 vaccine development efforts play a crucial role in driving the industry. PFE, MRK, NVS may prove to be good additions to your portfolio.
Merck (MRK) Gets FDA's Priority Review for Another Keytruda sBLA
by Zacks Equity Research
The FDA accepts Merck's (MRK) sBLA for Keytruda combo for first-line metastatic esophageal and gastroesophageal junction cancer, under a priority review. The FDA's verdict is awaited on Apr 13, 2021.
Pharma Stock Roundup: FDA Emergency Nod to PFE/BNTX COVID-19 Vaccine, AZN to Buy ALXN
by Kinjel Shah
FDA grants approval for emergency use of Pfizer's (PFE) COVID-19 vaccine. AstraZeneca (AZN) offers to buy Alexion.
TIPS ETFs to Buy for 2021 on Inflation Trade
by Sweta Killa
The COVID-19 vaccines and their availability have raised the prospect of inflation as we move ahead into the next year.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $79.83, moving -0.81% from the previous trading session.
AstraZeneca's (AZN) Triple Combo COPD Therapy Gets EU Nod
by Zacks Equity Research
AstraZeneca (AZN) gets European approval for triple combination therapy, Trixeo Aerosphere for COPD. CHMP recommends approval of trastuzumab deruxtecan for breast cancer.
Glaxo's (GSK) Rukobia Gets CHMP Nod for Heavily Pre-Treated HIV
by Zacks Equity Research
Glaxo (GSK) receives positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rukobia for treating HIV-1 infection in heavily pre-treated adult HIV patients.
Merck (MRK) Keytruda Gets CHMP Nod for First-Line Colon Cancer
by Zacks Equity Research
Merck's (MRK) regulatory application seeking label expansion of Keytruda as first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer gets positive CHMP opinion.
AstraZeneca (AZN) Stock Down on $39B Offer to Buy Alexion
by Zacks Equity Research
AstraZeneca (AZN) agrees to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest M&A deal ever.
Merck (MRK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $82.99 in the latest trading session, marking a -0.58% move from the prior day.
Inflation to Pick Up in 2021: Bet on TIPS ETFs
by Sweta Killa
The expectation for an uptick in inflation has led to investors' flocking to Treasury Inflation Protected Securities (TIPS) ETFs.
Emerging Markets Hit Record High: 5 Top-Performing ETFs YTD
by Sweta Killa
While many emerging market ETFs have been performing remarkably well, we highlight five funds that are leading the space from a year-to-date basis.
IPO Market Set to Thrive in December
by Zacks Equity Research
IPO Market Set to Thrive in December
DoorDash IPOs at $102, Vaccine Rally Cooling
by Mark Vickery
DoorDash is pricing its Initial Public Offering at $102 per share, for a valuation of $38.7 billion.
Pfizer (PFE) Pneumococcal Vaccine BLA Gets FDA's Priority Tag
by Zacks Equity Research
Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine candidate helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia.
Aligos (ALGS) Inks Collaboration With Merck for NASH Therapy
by Zacks Equity Research
Aligos (ALGS) signs an exclusive research collaboration agreement with Merck to discover and develop an oligonucleotide therapy for NASH. Shares rise.
Encouraging News on COVID-19 Vaccine
by Zacks Equity Research
Encouraging News on COVID-19 Vaccine
ADP Reports 307K New Jobs, Revisions Up
by Mark Vickery
307K new private-sector jobs was lower than expected, and beneath the upwardly revised 404K from October.
Pharma Stock Roundup: AZN COVID-19 Vaccine Interim Data, PFE Emergency Use Appeal
by Kinjel Shah
AstraZeneca (AZN) COVID-19 vaccine candidate proves effective in late-stage study. Pfizer (PFE) seeks Emergency use for its COVID-19 vaccine candidate.
Bristol Myers' (BMY) Opdivo Wins EC Nod for Esophageal Cancer
by Zacks Equity Research
Bristol Myers (BMY) obtains EC approval for Opdivo as a second-line treatment for unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.
Is Merck & Co (MRK) a Good Value Investor Stock Right Now?
by Zacks Equity Research
Let's see if Merck & Co (MRK) stock is a good choice for value-oriented investors right now from multiple angles.
Merck (MRK) to Buy OncoImmune, Add Late-Stage COVID-19 Treatment
by Zacks Equity Research
The acquisition of OncoImmune will boost Merck's (MRK) portfolio with CD24Fc, a candidate in phase III studies for the treatment of patients with severe and critical COVID-19.